Urine N-terminal pro b-type natriuretic peptide is predictive of heart failure-related emergency department visits.

Abstract

AimsEmergency department (ED) visits for decompensated heart failure (HF) are frequent and associated with poor long‐term outcomes in patients with HF. Serum N‐terminal pro b‐type natriuretic peptide (NT‐proBNP) is widely used to assist diagnosis and predict clinical outcomes in HF patients. Few studies have investigated the use of urine NT‐proBNP as an HF biomarker. This study aims to assess the value of urine NT‐proBNP for predicting ED visits for decompensated HF as compared with that of serum NT‐proBNP.Methods and resultsThis study included 122 HF patients with reduced left ventricular ejection fraction (<50%). Serum and urine NT‐proBNP levels were measured. Baseline data included demographics, comorbidities, and co‐medications. Medical records were used to determine the incidence of visits to the ED for decompensated HF during the 3 months following the last visit. We observed significantly higher levels of both serum and urine NT‐proBNP in patients with subsequent ED visits than in those without. Multivariate logistic regression analysis showed that urine NT‐proBNP/creatinine ratio (OR, 1.031; 95% CI, 1.001–1.061; P = 0.046) but not serum NT‐proBNP was an independent factor associated with subsequent ED visits. According to receiver‐operating characteristic‑area under the curve analysis, the optimal cut‐off value of urine NT‐proBNP/creatinine ratio for predicting subsequent heart‐failure related ED visits was 0.272 pg/μg Cr (area under the curve, 0.675; P = 0.011).ConclusionsFor HF patients with reduced left ventricular ejection fraction, a single measurement of urinary NT‐proBNP/creatinine ratio is predictive of subsequent ED visits for decompensated HF. This non‐invasive and easy measurement may be a clinically useful tool for monitoring clinical outcomes and identifying a subset of patients at higher risk of ED visits within a short time.